Additionally, some pediatric patients have experienced eye-related side effects such as uveitis and retinal vein blockage.[10,20–22] Overall, while the combination of dabrafenib and trametinib shows a demonstrates a manageable safety profile and good tolerability in treating pediatric gliomas with BRAF mutations, vigilant monitoring and proactive management of adverse events (AEs) are crucial to ensuring optimal outcomes for young patients. Here, BRAF is linked to glioma.